AFM
PDSB icon

Anson Funds Management’s PDS Biotechnology PDSB Stock Holding History

Anson Funds Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,171
Closed -$78K – 42
2018
Q4 		$78K Buy
+12,171
New +$161K 0.05% 47

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Anson Funds Management's PDSB Position: Q1 2019 in Review

Anson Funds Management sold out of PDS Biotechnology (PDSB) in Q1 2019, closing a stake of 12,171 shares — an estimated $78K sold.

Anson Funds Management first reported a position in PDSB in Q4 2018 and held it in 1 quarter. The position peaked at $78K in Q4 2018. 17 funds tracked by Wall St. Rank hold PDSB as of Q1 2019.

  • Anson Funds Management reported no remaining PDS Biotechnology position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 12,171 PDS Biotechnology shares in Q1 2019, an estimated $78K.
  • Anson Funds Management first reported a position in PDS Biotechnology in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's PDS Biotechnology position peaked at $78K in Q4 2018.
  • 17 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.